|
Treatment >
Treatment Surveys
|
|
The Oncologist, Vol. 11, No. 2, 152-164, February 2006.
(Review Article)
|
|
|
|
|
Abstract |
|
|
|
Therapeutic Advances in the Treatment
of Glioblastoma: Rationale and Potential Role of Targeted Agents
David A. Reardona,
Patrick Y. Wenb
|
|
|
|
|
|
|
|
Despite advances in standard therapy,
including surgical resection followed by radiation and
chemotherapy, the prognosis for patients with glioblastoma
multiforme (GBM) remains poor.
Unfortunately, most patients die within 2 years of
diagnosis of their disease.
Molecular abnormalities vary among individual patients and also within
each tumor.
Indeed, one of the distinguishing features of GBM is its
marked genetic heterogeneity.
Nonetheless, recent developments in the field of tumor
biology have elucidated signaling pathways and genes
involved in the development of GBM, and several novel
agents that target these signaling pathways are being developed.
As new details on the genetic characteristics of this
disease become available, innovative treatment regimens, including
a variety of traditional treatment modalities such as
surgery, radiation, and cytotoxic chemotherapy, will be combined with
newer targeted therapies.
This review introduces these new targeted therapies in the
context of current treatment options for patients with GBM.
It is hoped that this combined approach will overcome the
current limitations in the treatment of patients with GBM
and result in a better prognosis for these patients.
|
|
|
|
|
|
|
|
aPreston Robert Tisch
Brain Tumor Center, Duke University Medical Center, Durham, North
Carolina, USA; bCenter for NeuroOncology, Dana
Farber/Brigham and Women’s Cancer Center, Boston, Massachusetts, USA.
Correspondence: David A. Reardon, M.D., Preston Robert Tisch Brain
Tumor Center, Duke University Medical Center, DUMC 3624, Durham, North
Carolina 27710, USA. Telephone: 919-684-3457; Fax: 919-684-6674;
e-mail: reard003@mc.duke.edu and Patrick Y. Wen,
M.D., Center for NeuroOncology, Dana Farber/Brigham and Women’s
Cancer Center, 44 Binney Street, Boston, Massachusetts 02115, USA.
Telephone: 617-632-2166; Fax: 617-632-4773; e-mail: patrick_wen@dfci.harvard.edu
.
Received September 1, 2005; accepted for publication December 8, 2005.
|
|
|
Key Words. Angiogenesis
inhibitors, Glioblastoma multiforme, Targeted therapy, Tyrosine kinase
inhibitors
|
|
|
|
|
|
© 2006 AlphaMed Press
|
|
|
DOI: http://dx.doi.org/10.1634/theoncologist.11-2-152
|
|
|
Source: http://theoncologist.alphamedpress.org/cgi/content/abstract/11/2/152
|
|
|
HTML
Full Text: http://theoncologist.alphamedpress.org/cgi/content/full/11/2/152
|
|
|
PDF
Full Text: http://theoncologist.alphamedpress.org/cgi/reprint/11/2/152
|
|
|
|
